2025-10-05 - Analysis Report
Okay, here's an analysis of TEM (Unknown Company) based on the provided information, presented in English with a focus on key data points and a concise interpretation.

## TEM (Unknown Company) Analysis

**Company Overview:** Unknown Company, operating under the ticker TEM.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return (TEM):** 46.86%
*   **Cumulative Return (VOO):** 27.73%
*   **Absolute Divergence:** 15.6%
*   **Relative Divergence:** 48.9% (This means TEM's outperformance is at the 48.9th percentile of its historical range relative to VOO).

**Analysis:** TEM has significantly outperformed the S&P 500 (VOO) since its inception. While the absolute divergence is 15.6%, the relative divergence of 48.9 suggests that it is in the middle range of its historic relative performance, and doesn't guarantee future outperformance.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
| ---------- | ----- | ----- | ----- | ---- | ------ |
| 2023-2025  | 47.0% | 70.1% | 20.0% | 0.3  | 15.9   |

**Analysis:** The data shows high CAGR (47.0%), which is attractive, but also high MDD (70.1%) which represents a large risk factor. TEM is less volatile than the market (Beta = 0.3), and generates alpha (20.0%) meaning it has outperformed its benchmark index.

### 2. Recent Stock Price Movement

*   **Current Price:** $91.66
*   **Last Market Change:** +$2.64 (Previous Close: $89.30) - Reflects Recent Upward Momentum
*   **5-Day Moving Average:** $85.80
*   **20-Day Moving Average:** $83.97
*   **60-Day Moving Average:** $72.24

**Analysis:** The current price is above all three moving averages, suggesting a short-term and medium-term bullish trend. The recent positive change in the last market indicates an accelerated upward trend.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 61.06
*   **PPO:** 0.16
*   **Hybrid Signal:** Buy 100% of cash (11 shares - Very Safe - MRI:0.90)
*   **20-Day Relative Divergence Change:** +12.6% (Indicates Short-Term Increase in Outperformance)
*   **Expected Return:** NaN%

**Analysis:** The MRI of 0.9 signals a high investment recommendation based on risk assessment. RSI is at 61.06, indicating neither overbought nor oversold conditions. The positive change in relative divergence suggests short-term increasing momentum. The "Hybrid Signal" recommends a full investment strategy. Expected Return is not available. The price change of +$2.64 is significant and suggests recent positive momentum.

### 4. Recent News & Significant Events

*   **Oct 01, 2025:** Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution
*   **Sep 29, 2025:** Tempus AI (TEM): Assessing Valuation as Investor Interest Grows Without Clear Catalysts
*   **Sep 26, 2025:** TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now?
*   **Sep 22, 2025:** Tempus AI Pulls Back From Record High After Another FDA Clearance
*   **Sep 22, 2025:** Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD
*   **Sep 21, 2025:** Tempus AI Surges Since IPO as FDA Clearance Boosts Growth Outlook

**Analysis:** Recent news indicates positive developments, including FDA clearance, which fuels growth outlook, and investor interest. However, one article also mentions assessing valuation without clear catalysts, which may indicate concerns about overvaluation.

#### 4-2) Analyst Opinions

*   **Consensus:** Buy (Mean: 2.15)
*   **Target Price:** $77.55 (Average) / $100.00 (High) / $60.00 (Low)

**Analysis:** The analyst consensus is "Buy," but the average target price ($77.55) is *below* the current price ($91.66). This suggests that while analysts are generally positive, they may believe the stock is currently overvalued. The large range in target prices (60 to 100) reflects uncertainty among analysts.

### 5. Recent Earnings Analysis

| Date       | EPS   | Expected EPS |
| ---------- | ----- | ------------ |
| 2025-08-08 | -0.22 | -0.22988     |
| 2025-05-06 | -0.24 | -0.26003     |
| 2025-02-24 | -0.18 | -0.15        |
| 2024-11-04 | -0.25 | -0.26608     |
| 2024-08-06 | -0.63 | -0.59        |

**Analysis:** The company is consistently reporting negative EPS. However, in most quarters, the actual EPS is better than expected, indicating that the company is managing to beat expectations, or analysts are not correctly assessing the company.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | ------------- |
| 2025-06-30 | $0.31B   | 61.99%       |
| 2025-03-31 | $0.26B   | 60.69%       |
| 2024-12-31 | $0.20B   | 60.83%       |
| 2024-09-30 | $0.18B   | 58.50%       |
| 2024-06-30 | $0.17B   | 45.50%       |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
| ---------- | --------- | --------- |
| 2025-06-30 | $0.31B   | -13.84%   |
| 2025-03-31 | $0.33B   | -20.86%   |
| 2024-12-31 | $0.06B   | -23.10%   |
| 2024-09-30 | $0.05B   | -141.16%  |
| 2024-06-30 | $0.10B   | -562.04%  |

**Analysis:** Revenue is growing consistently quarter-over-quarter, and the profit margin is high and improving. However, Return on Equity (ROE) is negative, likely due to negative earnings, indicating that the company is not effectively generating profit from shareholder equity.

### 7. Overall Assessment

TEM (Unknown Company) shows strong revenue growth and high profit margins. The stock has significantly outperformed the S&P 500, and recent news events are generally positive, particularly the FDA clearance.

**However, there are key concerns:**

*   **Negative Earnings:** The company consistently reports negative EPS and ROE. While revenue is growing, it's not yet translating into profitability.
*   **Analyst Target Price vs. Current Price:** The average analyst target price is below the current stock price, suggesting potential overvaluation.
*   **Valuation Concerns:** The news articles mentioning assessing valuation without clear catalysts indicate possible concerns about the current valuation.

**In summary:** TEM is a high-growth company with promising technology, but investors should be cautious due to its lack of profitability and potential overvaluation. The company's future success will depend on its ability to convert revenue growth into positive earnings.
